Actively Recruiting
Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients
Led by Medical University of Vienna · Updated on 2026-04-17
20
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP/GLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.
CONDITIONS
Official Title
Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 18 years or older
- Signed informed consent
- Previously diagnosed diabetes mellitus
- Normal eye exam except for diabetic retinopathy, unless abnormalities are clinically irrelevant
- Planned start of therapy with GLP-1 receptor agonists (semaglutide, liraglutide) or GIP/GLP-1 receptor agonist (tirzepatide) by a diabetes specialist
You will not qualify if you...
- Participation in another clinical trial within 3 weeks before screening
- Symptoms of a relevant illness within 3 weeks before the first study day
- Severe medical conditions other than diabetes as judged by the investigator
- Alcohol abuse
- Blood donation in the previous 3 weeks
- Any eye abnormalities preventing reliable measurements in the study eye
- Previous laser photocoagulation treatment in the study eye
- Best corrected visual acuity less than 0.4 Snellen
- Women of childbearing potential not using effective contraception
- Pregnancy, planned pregnancy, or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medical University Vienna
Vienna, State of Vienna, Austria, 1090
Actively Recruiting
Research Team
D
Doreen Schmidl, Prof. Priv. Doz. MD.; PhD
CONTACT
D
Doreen Schmidl, Prof. Priv. Doz. MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here